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Abstract: The treatment of children with inborn errors of metabolism (IEM) is mainly 
based on restricted dietary intake of protein-containing foods. However, dietary protein 
restriction may not only reduce amino acid intake, but may be associated with low intake 
of polyunsaturated fatty acids as well. This review focuses on the consequences of dietary 
restriction  in  IEM  on  the  bioavailability  of  long-chain  polyunsaturated  fatty  acids 
(LCPUFAs)  and  on  the  attempts  to  ameliorate  these  consequences.  We  were  able  to 
identify during a literature search 10 observational studies investigating LCPUFA status in 
patients  with  IEM  and  six  randomized  controlled  trials  (RCTs)  reporting  effect  of 
LCPUFA supplementation to the diet of children with IEM. Decreased LCPUFA status, in 
particular  decreased  docosahexaenoic  acid  (DHA)  status,  has  been  found  in  patients 
suffering  from  IEM  based  on  the  evidence  of  observational  studies.  LCPUFA 
supplementation effectively improves DHA status without detectable adverse reactions. 
Further  research  should  focus  on  functional  outcomes  of  LCPUFA  supplementation  in 
children with IEM.  
Keywords: inborn errors of metabolism; long-chain polyunsaturated fatty acids; linoleic 
acid; alpha-linolenic acid; arachidonic acid; docosahexaenoic acid  
Abbreviations: AA: arachidonic acid; ALA: α-linolenic acid; DHA: docosahexaenoic acid; 
E:  erythrocyte;  EPA:  eicosapentaenoic  acid;  EPC:  erythrocyte  phosphatidylcholine;  
EPEA:  erythrocyte  phosphatidylethanolamine;  EPL:  erythrocyte  phospholipid;  
HPA:  hyperphenylalaninemia;  LA:  linoleic  acid;  MMA:  methylmalonic  academia;  
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MSUD:  maple  syrup  urine  disease;  P:  plasma;  PA:  propionic  acidemia;  
PCE:  plasma  cholesteryl  ester;  PKU:  phenylketonuria;  PPL:  plasma  phospholipid;  
PTG: plasma triacylglycerol  
 
1. Introduction 
Inborn errors of metabolism (IEM) represent a highly heterogeneous group of genetic conditions, in 
which single gene defects are responsible for a block in the metabolic pathway. The block can either 
be  caused  by  the  loss  of  function  of  mutant  enzymes  or  defects  of  transporters.  Pathological 
consequences are due to direct toxicity of accumulating substrates before the block, deficiency of 
products beyond the block, activation of alternative metabolic pathways leading to alternative metabolite 
production,  or  a  combination  of  these  factors  [1].  Most  IEM  are  autosomal  recessive  disorders; 
however, some of them are inherited in an X-linked recessive manner. Though many diseases caused 
by IEM are individually rare (some of them less than 1 per 100,000 births); their cumulative incidence 
may approach 1 per 800 to 2,500 births [2], representing thereby a serious health concern. 
Neonates with IEM usually appear normal at birth, because toxic metabolites can cross the placenta 
and can be eliminated by the mothers. The first clinical symptoms may appear within the time interval 
of hours to months after birth; however, diagnoses established in childhood or even in adulthood are 
not  exceptional  [3]. Common symptoms  are  lethargy,  poor  feeding,  vomiting,  respiratory  distress, 
seizures  and  psychomotor  or  developmental  delay  [3,4].  However,  today  several  IEMs  can  be 
diagnosed early by neonatal screening and treatment can be initiated pre-symptomatically. 
Symptoms of acute encephalopathy are particularly characteristic to patients with organic acidemias 
(e.g.,  maple  syrup  urine  disease,  propionic,  isovaleric,  and  methylmalonic  acidemias),  urea  cycle 
defects (e.g., ornithine transcarbamylase deficiency, citrullinemia) and some other disorders of amino 
acid metabolism (e.g., glutaric acidemia type I) [5]. Early dietary treatment with strict limitations of 
specific nutrient intake, together with rapid removal of toxic substrates and/or replacement of the 
deficient  products  are  the  main  therapeutic  measures  securing  long-term  survival  of  these  
patients [6,7]. Patients with severe IEMs have to avoid not only foods of animal origin, but usually 
also  some  plant-based  foods  with  high  protein  contents.  For  instance,  patients  with  severe 
hyperphenylalaninemia can usually tolerate only 200–400 mg phenylalanine intake, which equals to 
120–240 mL of cow’s milk or 80–160 g of beans per day. The severe dietary protein restriction can be 
compensated by consuming special amino acid mixtures that are devoid of the critical amino acids. 
Still, dietary protein restriction may lead both to reduced amino acid intake and to low intake of 
important other nutrients, such as vitamins, trace elements, and polyunsaturated fatty acids as well [8,9]. 
This  review  discusses  the  potential  consequences  of  reduced  bioavailability  of  long-chain 
polyunsaturated fatty acids (LCPUFAs). 
2. Long-Chain Polyunsaturated Fatty Acids 
LCPUFAs are important components of membrane lipids in all tissues. The most important of them 
are the omega-6 essential fatty acid, linoleic acid (C18:2n-6, LA), and the omega-3 essential fatty acid, Nutrients 2010, 2  
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α-linolenic  acid  (C18:3n-3,  ALA),  as  well  as  their  longer-chain  metabolites,  arachidonic  acid  
(C20:4n-6,  AA)  and  docosahexaenoic  acid  (C22:6n-3,  DHA).  LCPUFAs  increase  the  fluidity, 
flexibility and permeability of cell membranes, the number of receptors and the affinity of receptors to 
their  substrates:  hormones,  growth  factors,  and  proteins.  Moreover,  some  LCPUFAs  are  also 
precursors of several second messengers. Omega-6 fatty acids, mainly AA and dihomo-γ-linolenic acid 
(C20:3n-6),  are  predominantly  precursors  of  proinflammatoric  prostaglandins,  thromboxans  and 
leucotriens, while omega-3 fatty acids, mainly eicosapentaenoic acid (C20:5n-3, EPA), are precursors 
of antiinflammatory eicosanoids. AA and DHA are concentrated in the central nervous system, as well 
as in the retina, heart and skeletal muscle, and play an important role in the maintenance of normal 
development and normal neural functions [10]. 
Vegetables  are  good  sources  of  essential  fatty  acids;  however,  their  preformed  long-chain 
metabolites are found mainly in animal foods. Food products of terrestrial animals are rich in omega-6 
fatty acids, whereas sea fishes are rich in omega-3 fatty acids [11]. Mammals, including humans, 
cannot synthesize essential fatty acids; therefore they have to consume them in the diet from dietary 
sources. The enzymatic reactions of Δ-6- and Δ-5 desaturation and elongation of essential fatty acids 
convert LA to AA and ALA to EPA. While AA is the major product of the omega-6 fatty acid family, 
EPA is an intermediate, which needs further elongation, Δ-6 desaturation and peroxysomal β-oxidation to 
be converted into the biologically most important product, DHA (Figure 1) [12]. 
Figure 1. Metabolism of the omega-6 and omega-3 fatty acids. 
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The conversion of LA to AA is more efficient than the conversion of ALA to DHA, because AA 
synthesis is less complex than DHA synthesis. In healthy individuals, the conversion rate of ALA to 
EPA is less than 5 to 10% and to DHA is only 2 to 5% [13]. Because the elongation reactions are 
rapid,  desaturation  reactions  represent  the  rate-limiting  steps  [11].  Moreover,  essential  fatty  acid 
content  of  the  diet  can  also  influence  the  conversion  rates;  because  the  involvement  of  the  same 
enzymes in the synthesis of the two fatty acid families leads to strong metabolic competition between 
omega-6 and omega-3 fatty acids. Due to the relatively limited effectiveness of endogenous DHA 
synthesis, the DHA status is determined dominantly by dietary intake of preformed DHA [14]. It has 
been demonstrated in numerous studies that vegans and vegetarians, who have diets high in LA, have a 
lower omega-3 LCPUFA status than omnivores (lower EPA and DHA) [15]. 
3. Literature Search 
We conducted a MEDLINE literature search using the PubMed as well as OVID interface; Scopus 
and the Cochrane Library CENTRAL databases were also searched from inception to May 2010. Text 
terms with appropriate truncation and indexing terms were used to identify articles eligible for review. 
The search was in the following form: [(IEM terms) AND (LCPUFA terms)]. The searches were 
supplemented with hand searches of journals and the reference lists from relevant articles located were 
used to identify additional sources. We did not apply any language restriction.  
4. Long-Chain Polyunsaturated Fatty Acids in Inborn Errors of Metabolism 
Despite  the  early  initiation  of  treatment,  patients  with  IEM  usually  suffer  from  long-term 
neurological complications; mainly brain structural changes and abnormalities of the visual function 
have  been  shown  in  patients  who  are  otherwise  well-controlled  during  childhood,  e.g.,  patients 
suffering from hyperphenylalaninemia [16]. There is considerable interest in the potential roles that 
LCPUFAs play in neurological development throughout childhood. It seems possible that LCPUFA 
deficiency induced by the dietary treatment may also contribute to neurological abnormalities.  
During fetal life, LCPUFAs are provided by placental transfer; thereafter, these fatty acids are 
provided either in breast milk or in infant formulas. Human milk is a relatively low-protein food, it 
contains LCPUFAs and many other bioactive compounds; nevertheless, breastfeeding contributes only 
a relatively small extent to the nutrition of infants with IEM [17,18]. Because of the limited dietary 
intake  of  preformed  omega-6  and  omega-3  LCPUFAs,  many  patients  with  IEM  must  rely  on the 
endogenous synthesis of LCPUFAs from their precursors, LA and ALA [14].  
4.1. Observational studies 
Fatty acid status has been investigated in several groups of patients with different IEM (Table 1). 
The majority of studies were carried out in PKU children, but patients with other inborn errors of 
amino  acid  metabolism  were  also  investigated.  Numerous  lipid  classes  were  analyzed  in  order  to 
reveal potential differences between fatty acid profiles of patients with IEM and healthy, age-matched 
controls. In five studies, AA levels did not differ in patients and controls [19-23]; this finding indicates 
that  most  patients  investigated  in  these  studies  can  maintain  normal  AA  status,  if  LA  intake  is Nutrients 2010, 2  
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adequate. However, in four studies, patients with IEM have been found to have significantly lower 
plasma  AA  levels  than  that  of  the  controls,  in  spite  of  equal  [24,25]  or  even  significantly  
higher  [26,27]  values of the precursor essential  fatty  acid, LA. Even more marked reduction was 
observed in DHA status in patients with IEM. DHA levels were significantly lower in patients with 
IEM compared to healthy controls in eight studies, whereas in two studies [19,21], DHA levels did not 
differ between patients and controls. The most important intermediate metabolite of DHA synthesis, 
EPA,  showed  significantly  lower  levels  in  patients  than  in  controls  in  eight  studies,  whereas  no 
differences were seen in two other studies [19,23]. No clear picture of the availability of the precursor 
omega-3 essential fatty acid, ALA was seen in the studies reviewed (Table 1). 
Table 1. Observational studies on the availability of long-chain polyunsaturated fatty acids 
in inborn errors of metabolism. Number of participants in the IEM* group: methylmalonic 
acidemia  (5),  ornithine  transcarbamylase  deficiency  (7),  citrullinemia  (1);  number  of 
participants in the IEM** group: ornithine transcarbamylase deficency (7), argininosuccinic 
aciduria  (4),  methylmalonic  acidemia  (6),  PA  (3),  MSUD  (1),  tyrosinemia  type  I  (5), 
classical  homocystinuria  (4),  lysinuric  protein  intolerance  (1),  2-amino-/2-oxoadipic 
aciduria (1), hyperinsulinaemia–hyperammonaemia syndrome (1); medical food for patients: 
a: Phenex-1, -2; 
b: Phenyl-Free; 
c: XP Maxamaid/Maxamum. n.d.: no data; ↑: patients had 
significantly higher values (p < 0.05) than healthy controls; ↓: patients had significantly 
lower  values  (p  <  0.05)  than  healthy  controls;  —:  no  significant  difference  between 
patients and healthy controls.  
Study  Number of participants, age  Biomarker  LA  AA  ALA  EPA  DHA 
Galli et al., 
1991 [24] 
PKU(15)–Control(12) 
3–12 yr 
P  —  ↓  n.d.  ↓  ↓ 
PPL  —  ↓  n.d.  —  ↓ 
PCE  —  —  n.d.  n.d.  n.d. 
E  —  —  n.d.  —  — 
Sanjurjo et al., 
1994 [28] 
PKU(40)–Control(50) 
2 mo–20 yr 
P  ↑  ↓  —  —  ↓ 
EPL  —  ↑  ↓  ↓  ↓ 
Sanjurjo et al., 
1997 [26] 
IEM*(13)–Control(50) 
1–17 yr 
P  ↑  ↓  ↓  ↓  ↓ 
EPL  ↑  —  ↓  —  ↓ 
Decsi et al., 
1997 [19] 
PA(5)–Control(18) 
3.5–9.5 yr 
PPL  —  —  —  —  — 
PTG  —  —  —  —  — 
PCE  —  —  —  —  — 
Pö ge et al., 
1998 [20] 
PKU(8)–Control(12) 
1 
PKU(9)–Control(8) 
2 
1: 1–6 yr; 
2: 11–18 yr 
PPL 
—  —  —  —  — 
—  —  —  —  — 
PCE 
—  —  —  —  ↓ 
—  —  —  —  — 
EPC 
—  —  —  —  ↓ 
—  —  —  —  — 
EPEA 
—  —  —  ↓  ↓ 
—  —  —  —  — 
van Gool et al., 
2000 [27] 
PKU(9)–Control(18) 
6 mo–25 yr 
PPL  —  —  ↓  ↓  ↓ 
EPL  ↑  ↓  ↓  ↓  ↓ Nutrients 2010, 2  
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Table 1. Cont. 
Acosta et al., 
2001 [21] 
PKU(13)–Control(13) 
a 
PKU(7)–Control(6) 
b 
PKU(8)–Control(7) 
c 
1–13 yr 
P 
—  —  ↑  —  — 
—  —  —  ↓  — 
—  —  —  —  — 
E 
↑  —  —  —  — 
—  —  —  —  — 
—  —  —  —  — 
Moseley et al., 
2002 [25] 
PKU(27)–Control(120) 
7–39 yr 
P  —  ↓  ↑  ↓  ↓ 
E  —  —  —  ↓  ↓ 
Vlaardingerbroek et al., 
2006 [22] 
IEM**(33)–Control(38) 
1–18 yr 
PPL  ↑  —  ↑  ↓  ↓ 
EPL  —  —  —  ↓  ↓ 
Mazer et al., 
2010 [23] 
MSUD(6)–Control(12) 
12–30 yr 
P  —  —  ↑  —  ↓ 
E  —  —  ↑  —  ↓ 
4.2. Randomized controlled trials 
We  were  able  to  identify  six  randomized  controlled  trials  (RCTs)  on  the  effect  of  LCPUFA 
supplementation  in  patients  with  IEM  (Table  2).  In  two  studies,  infants  with  PKU  consumed 
phenylalanine-free infant formula with or without LCPUFA for one year [29,30]. At the end of the 
intervention, DHA levels were significantly higher in supplemented than in control infants, whereas 
AA levels did not differ between the groups. Neither in visual evoked potentials, nor in mental and 
psychomotor development indices (Bayley Test) were differences reported between supplemented and 
control infants in one of these studies [29]. 
In the other four RCTs, children either with PKU (three studies) or with MMA (one study) were 
supplemented  with  LCPUFA.  In  a  single  blind  placebo  controlled  trial,  children  with  PKU  were 
randomized  to  fish  oil  or  blackcurrant  oil  supplementation  [31].  After  six  months  of  dietary 
intervention,  subjects  receiving  fish  oil  showed  significantly  higher  EPA  and  DHA  values  than 
controls; moreover, significantly decreased plasma triacylglycerol values was observed in the fish oil 
group. In a double blind, placebo controlled trial children with PKU received capsules containing 
either  equivalent  amounts  of  omega-6  and  omega-3  LCPUFAs  or  placebo.  DHA  levels  in  the 
supplemented group increased by around 100%; whereas AA and EPA level remained almost the  
same  [16,32,33].  By  the  end  of  the  study,  P100  wave  latency  decreased  significantly  in  the 
supplemented group; however, P100 wave latency returned to the baseline after three years [33]. In 
another open-labelled, randomized supplementation trial [34], children with PKU received fat-free 
protein substitute with or without essential fatty acids for 20 weeks. DHA level increased significantly; 
however AA levels did not increase over the study period. In an open-labeled, randomized study of 
crossover design, children with MMA received DHA treatment or placebo [35]. Plasma DHA level 
increased and triacylglycerol levels decreased significantly with DHA therapy. It is to be emphasized that 
none of the studies summarized in Table 2 reported any adverse reactions to LCPUFA supplementation. 
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Table 2. Randomized controlled trials on the effect of long-chain polyunsaturated fatty acid supplementation in inborn errors of metabolism. 
*: % DHA/total fatty acid composition; a: mean (SD); b: mean (range); ↑: significant increase (p < 0.05) in the supplemented group compared 
with the control group at the end of the intervention; ↓: significant decrease (p < 0.05) in the supplemented group compared with the control 
group at the end of the intervention; —: no significant difference between the treatment and the control group at the end of the intervention. 
Study 
Number of 
participants; age 
Short description of 
intervention 
Biomarker 
DHA * 
(treatment vs. control group) 
Clinical outcomes 
[29] 
42 infants with PKU  
(21 in treatment and 21 in 
control group); 8–39 days 
Supplemented formula (0.7 g AA 
and 0.3 g DHA/100 g fatty acids) 
for 1 yr 
EPL  3.60 (1.06) vs. 1.40 (0.44) 
a↑  — P1 and P100 latency;  
— mental and physical 
development (Bayley Test); 
no adverse reactions 
[30] 
21 infants with PKU  
(10 in treatment and 11 in 
control group); <4 wk 
Supplemented formula (0.46 g AA 
and 0.27 g DHA/100 g fatty acids) 
for 1 yr 
PPL  3.08 (0.10) vs. 1.52 (0.19) 
a↑  no adverse reactions 
[31] 
21 children with PKU  
(10 in treatment and 11 in 
control group); 5–10 yr 
2.5–4 g fish oil (18 g EPA, 4 g 
DPA and 12 g DHA/100 g fatty 
acid) daily for 6 mo 
P  2.94 (0.88) vs. 0.73 (0.08) 
a↑  ↓ plasma triacylglycerol;  
no adverse reactions 
[16,32,33] 
20 children with HPA  
(10 in treatment and 10 in 
control group); 10 ±  7 yr 
1 capsule (37 mg AA, 27.5 mg 
EPA, 20 mg DPA and 40 mg 
DHA/0.5 g capsule) per 4 kg body 
weight for 1 yr 
P  2.3 (1.1) vs. 1.1 (0.3) 
a↑  ↓ P100 wave latency;  
— plasma triacylglycerol;  
no adverse reactions 
PPL  3.1 (1.6) vs. 1.6 (0.4) 
a↑ 
PTG  0.6 (0.5) vs. 0.3 (0.3) 
a— 
PCE  0.5 (0.2) vs. 0.2 (0.1) 
a↑ 
E  2.8 (1.5) vs. 1.5 (0.5) 
a— 
EPC  0.9 (0.3) vs. 0.4 (0.2) 
a↑ 
EPEA  3.7 (1.7) vs. 1.3 (0.9) 
a↑ 
[34] 
44 children with PKU  
(24 in treatment and 20 in 
control group); 1–10 yr 
EFA supplemented protein 
substitute (17.2 g LA and 4.5 g 
ALA/100 g fatty acid) for 20 wk 
EPL  2.07 (0.8) vs. 1.64 (0.4) 
a↑  no adverse reactions 
[35] 
4 children with MMA;  
9–16 yr; crossover design 
25 mg/kg DHA daily for 3 mo  P  5.14 (2.72–7.94) vs.  
1.89 (1.12–2.31) 
b↑ 
↓ plasma triacylglycerol;  
no adverse reactions 
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5. Conclusions 
From observation trials there is convincing evidence indicating that patients suffering from IEM 
have lower contribution of LCPUFA, especially of DHA, to the fatty acid composition of various 
plasma and erythrocyte membrane lipids than healthy controls. From RCTs there is firm evidence 
showing  that  LCPUFA  supplementation  results  in  higher  DHA  status  without  detectable  adverse 
reactions.  The  limited  data  available  on  functional  consequences  of  LCPUFA  supplementation  in 
children with IEM do not allow any firm conclusion to be drawn as yet. Further research should focus 
on functional outcomes of LCPUFA supplementation in children with IEM. 
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